Anuh Pharma reported a 47.3% surge in net profit for the second quarter ended September 30, 2026, reaching Rs 11.21 crore despite flat revenue growth. The company successfully improved its EBITDA margin to 9.47%, reflecting enhanced operational efficiency. Investors should note the positive reduction in trade receivables, which signals better working capital management for the pharmaceutical player.
Anuh Pharma Q2 Net Profit Climbs 47% on Better Margins
Net profit reached Rs 11.21 crore in Q2 2026, up from Rs 7.61 crore year-on-year.
Revenue from operations stood at Rs 185.24 crore, showing a minor 0.3% decline.
Reader Takeaway: Profitability spiked due to improved EBITDA margins, though the company must now focus on reviving top-line revenue growth.
What just happened
Anuh Pharma Ltd released its unaudited financial results for the quarter ending September 30, 2026. While topline revenue remained virtually unchanged at Rs 185.24 crore compared to Rs 185.88 crore in the same period last year, the company demonstrated a strong performance in profitability. Net profit grew by 47.3% to Rs 11.21 crore. The Board of Directors approved these results on October 30, 2026, following a review by the Audit Committee.
Why this matters
The jump in profitability despite flat revenue indicates better operational efficiency. The company’s EBITDA margin rose to 9.47%, a significant increase from 6.92% in the previous year's second quarter. This suggests that Anuh Pharma is managing its input costs and operational expenses more effectively, which is a crucial development for bottom-line stability.
Balance Sheet and Cash Flow
Anuh Pharma reported total assets of Rs 553.66 crore as of September 30, 2026. A key highlight in the balance sheet is the effective management of trade receivables, which dropped to Rs 189.78 crore from Rs 238.63 crore in March 2026. This indicates faster cash collection. Conversely, inventories increased to Rs 172.45 crore. The company generated a healthy net cash inflow from operations of Rs 26.68 crore for the half-year.
What to track next
Moving forward, investors should watch for sustained revenue growth. While margin expansion is a positive short-term driver, the company’s ability to scale its 'Bulk drug and Chemicals' segment will determine its long-term market competitiveness. The current inventory buildup should also be monitored to ensure it does not negatively impact future working capital cycles.